Aura Biosciences Statistics
Total Valuation
AURA has a market cap or net worth of $772.10 million. The enterprise value is $674.35 million.
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026, before market open.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AURA has 110.30 million shares outstanding. The number of shares has increased by 29.81% in one year.
| Current Share Class | 110.30M |
| Shares Outstanding | 110.30M |
| Shares Change (YoY) | +29.81% |
| Shares Change (QoQ) | +0.52% |
| Owned by Insiders (%) | 1.11% |
| Owned by Institutions (%) | 43.56% |
| Float | 99.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.19 |
| P/TBV Ratio | 7.20 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.09, with a Debt / Equity ratio of 0.16.
| Current Ratio | 7.09 |
| Quick Ratio | 6.87 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -95.57% and return on invested capital (ROIC) is -54.79%.
| Return on Equity (ROE) | -95.57% |
| Return on Assets (ROA) | -50.59% |
| Return on Invested Capital (ROIC) | -54.79% |
| Return on Capital Employed (ROCE) | -98.06% |
| Weighted Average Cost of Capital (WACC) | 6.25% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$994,628 |
| Employee Count | 113 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AURA has paid $101,000 in taxes.
| Income Tax | 101,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.55% in the last 52 weeks. The beta is 0.39, so AURA's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | +6.55% |
| 50-Day Moving Average | 7.23 |
| 200-Day Moving Average | 6.26 |
| Relative Strength Index (RSI) | 52.93 |
| Average Volume (20 Days) | 605,538 |
Short Selling Information
The latest short interest is 5.39 million, so 4.88% of the outstanding shares have been sold short.
| Short Interest | 5.39M |
| Short Previous Month | 3.76M |
| Short % of Shares Out | 4.88% |
| Short % of Float | 5.41% |
| Short Ratio (days to cover) | 4.69 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -118.62M |
| Pretax Income | -112.29M |
| Net Income | -112.39M |
| EBITDA | -117.51M |
| EBIT | -118.62M |
| Earnings Per Share (EPS) | -$1.74 |
Full Income StatementBalance Sheet
The company has $114.73 million in cash and $16.99 million in debt, giving a net cash position of $97.74 million or $0.89 per share.
| Cash & Cash Equivalents | 114.73M |
| Total Debt | 16.99M |
| Net Cash | 97.74M |
| Net Cash Per Share | $0.89 |
| Equity (Book Value) | 107.25M |
| Book Value Per Share | 1.67 |
| Working Capital | 101.80M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$91.28 million and capital expenditures -$362,000, giving a free cash flow of -$91.64 million.
| Operating Cash Flow | -91.28M |
| Capital Expenditures | -362,000 |
| Depreciation & Amortization | 1.11M |
| Net Borrowing | n/a |
| Free Cash Flow | -91.64M |
| FCF Per Share | -$0.83 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |